Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-κB pathways

Thyroid

Volumn 18, Issue 8, 2008, Pages 853-864

  Liu, Dingxie ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZAMIDES; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DIPHENYLAMINE; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; MUTATION; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RAS PROTEINS; THYROID NEOPLASMS;

EID: 50649099936     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0357     Document Type: Article

References (40)

1. Torii S, Nakayama K, Yamamoto T, Nishida E 2004 Regulatory mechanisms and function of ERK MAP kinases. J Biochem 136:557-561.
2. MacCorkle RA, Tan TH 2005 Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43:451-461.
3. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F 2005 Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 70:461-467.
4. Kohno M, Pouyssegur J 2006 Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211.
5. Roberts PJ, Der CJ 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
6. Sebolt-Leopold JS, Herrera R 2004 Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947.
7. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N 2006 BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362.
8. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A NationalCancerDataBase reporton53,856casesof thyroidcarcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
9. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
10. Mazzaferri EL 2006 An overview of the management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P (eds) Practical Management of Thyroid Cancer: A Multidisciplinary Approach. Springer-Verlag, London, England, pp 1-28.
11. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK 2006 (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov=csr=1975_2003= based on November 2005 SEER data submission, posted to the SEER web site, 2006.
12. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 2002 PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023.
13. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752.
14. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
15. Liu D, Liu Z, Jiang D, Dackiw AP, Xing M 2007 Inhibitory effects of the MEK inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92:4686-4695.
16. Liu D, Liu Z, Condouris S, Xing M 2007 BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92:2264-2271.
17. Welkos S, O'Brien A 1994 Determination of median lethal and infectious doses in animal model systems. Methods Enzymol 235:29-39.
18. Barbacid M 1987 ras genes. Annu Rev Biochem 56:779-827.
19. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J 1996 Cyclin D1 expression is regulated positively by the p42=p44MAPK and negatively by the p38=HOGMAPK pathway. J Biol Chem 271:20608-20616.
20. Cheng M, Sexl V, Sherr CJ, Roussel MF 1998 Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 95:1091-1096.
21. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S, Leonardi A 2004 Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279:54610-54619.
22. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S 2004 Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. ClinCancer Res 10: 6821-6829.
23. Furuya F, Lu C, Willingham MC, Cheng SY 2007 Inhibition of phosphatidylinositol 30 kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28:2451-2458.
24. Mandal M, Kim S, Younes MN, Jasser SA, El Naggar AK, Mills GB, Myers JN 2005 The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92:1899-1905.
25. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693.
26. Vasko VV, Saji M 2007 Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19:11-17.
27. Hahn WC, Weinberg RA 2002 Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
28. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA 2008 RAFV600E mutation is associated with preferential sensitivity to MEK inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93:2194-2201.
29. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
30. Ain KB 2000 Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:615-629.
31. Fagin JA 2005 Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 116:259-269.
32. Ichihara M, Murakumo Y, Takahashi M 2004 RET and neuroendocrine tumors. Cancer Lett 204:197-211.
33. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM 2006 Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 22:627-636.
34. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC 2007 Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079.
35. Henderson YC, Fredrick MJ, Clayman GL 2007 Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Arch Otolaryngol Head Neck Surg 133:810-815.
36. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD 2007 Selective growth inhibition in BRAF mutant thyroid cancer by the MEK 1/2 inhibitor AZD6244 (ARRY-142886). J Clin Endocrinol Metab 92:4712-4718.
37. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih I 2005 Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994-2000.
38. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E 2007 Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase 1/2 inhibitor. Clin Cancer Res 13:1576-1583.
39. Sebolt-Leopold JS, Dudley DT, Herrera R, van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR 1999 Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816.
40. Arteaga CL, Baselga J 2004 Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5:525-553.